GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Quick Ratio

Shanghai Henlius Biotech (HKSE:02696) Quick Ratio : 0.33 (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Shanghai Henlius Biotech's quick ratio for the quarter that ended in Jun. 2024 was 0.33.

Shanghai Henlius Biotech has a quick ratio of 0.33. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Shanghai Henlius Biotech's Quick Ratio or its related term are showing as below:

HKSE:02696' s Quick Ratio Range Over the Past 10 Years
Min: 0.17   Med: 0.41   Max: 2.64
Current: 0.33

During the past 7 years, Shanghai Henlius Biotech's highest Quick Ratio was 2.64. The lowest was 0.17. And the median was 0.41.

HKSE:02696's Quick Ratio is ranked worse than
90.85% of 1498 companies
in the Biotechnology industry
Industry Median: 3.38 vs HKSE:02696: 0.33

Shanghai Henlius Biotech Quick Ratio Historical Data

The historical data trend for Shanghai Henlius Biotech's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Quick Ratio Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 2.64 0.81 0.41 0.29 0.38

Shanghai Henlius Biotech Quarterly Data
Dec17 Mar18 Jun18 Dec18 Mar19 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.29 0.37 0.34 0.38 0.33

Competitive Comparison of Shanghai Henlius Biotech's Quick Ratio

For the Biotechnology subindustry, Shanghai Henlius Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Henlius Biotech's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's Quick Ratio falls into.



Shanghai Henlius Biotech Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Shanghai Henlius Biotech's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(2926.987-828.383)/5542.651
=0.38

Shanghai Henlius Biotech's Quick Ratio for the quarter that ended in Jun. 2024 is calculated as

Quick Ratio (Q: Jun. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(2580.003-843.29)/5278.239
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Henlius Biotech  (HKSE:02696) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Shanghai Henlius Biotech Quick Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Henlius Biotech Business Description

Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Ubs Group Ag
Golden Valley Value Select Master Fund 2101 Beneficial owner
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Lvc Sg Management Pte. Ltd. 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lin Lijun 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Qatar Investment Authority 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you

Shanghai Henlius Biotech Headlines

No Headlines